Search results for "thrombocytosi"

showing 10 items of 24 documents

Platelet-Derived GARP Induces Peripheral Regulatory T Cells—Potential Impact on T Cell Suppression in Patients with Melanoma-Associated Thrombocytosis

2020

Platelets have been recently described as an important component of the innate and adaptive immunity through their interaction with immune cells. However, information on the platelet&ndash

0301 basic medicineCancer Researchmedicine.medical_treatmentT cellanimal diseaseschemical and pharmacologic phenomenathrombocytosisBiologylcsh:RC254-282Article03 medical and health sciences0302 clinical medicineImmune systemGARPDownregulation and upregulationmedicinemelanomaPlateletIL-2 receptorFOXP3Immunotherapybiochemical phenomena metabolism and nutritionAcquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensTreg030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisplateletsCancer researchbacteriaCancers
researchProduct

Clinical Features And Course Of Refractory Anemia With Ring Sideroblasts Associated With Marked Thrombocytosis

2012

Background Refractory anemia with ring sideroblasts associated with marked thrombocytosis was proposed as a provisional entity in the 2001 World Health Organization classification of myeloid neoplasms and also in the 2008 version, but its existence as a single entity is contested. We wish to define the clinical features of this rare myelodysplastic/myeloproliferative neoplasm and to compare its clinical outcome with that of refractory anemia with ring sideroblasts and essential thrombocythemia. Design and Methods We conducted a collaborative retrospective study across Europe. Our database included 200 patients diagnosed with refractory anemia with ring sideroblasts and marked thrombocytosis…

AdultBlood PlateletsMalemedicine.medical_specialtyAdolescentAnemiaAnèmiaRefractory anemia with ringed sideroblastsLower riskGastroenterologyRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHumansMyeloproliferative neoplasmSurvival analysisAgedRetrospective StudiesTumorsAged 80 and overThrombocytosisThrombocytosisPlatelet CountEssential thrombocythemiabusiness.industryAnemia RefractoryAnemiaHematologyJanus Kinase 2Middle Agedmedicine.diseaseSurvival AnalysisAnemia SideroblasticSurgeryEuropeRefractory anemia with ring sideroblastsMutationFemaleOriginal Articles and Brief ReportsbusinessThrombocythemia Essential
researchProduct

Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study.

1998

The present phase II study was undertaken to assess antitumoral activity, safety and tolerability of recombinant human interleukin-6 (rh IL-6) in patients with advanced renal cell cancer. Rh IL-6 was administered as a daily subcutaneous injection at a fixed dose of 150 micrograms/day for a maximum of 42 consecutive days. 12 patients with metastatic renal cell cancer without previous immunotherapy were enrolled and were evaluated for response. No objective clinical responses were observed in the trial. Toxicity was moderate and reversible and mainly comprised fever, influenza-like symptoms, fatigue and moderate hepatotoxicity. Anaemia, leucocytosis, thrombocytosis and induction of an acute p…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchAntineoplastic AgentsGastroenterologySubcutaneous injectionInternal medicinemedicineHumansTreatment FailureCarcinoma Renal CellAgedKidneyThrombocytosisbusiness.industryInterleukin-6CancerImmunotherapyMiddle Agedmedicine.diseaseKidney NeoplasmsRecombinant Proteinsmedicine.anatomical_structureC-Reactive ProteinOncologyTolerabilityImmunologyFemalebusinessKidney diseaseEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Abdominal aortic thrombosis secondary to reactive thrombocytosis in a patient with iron deficiency anemia

2016

Adultmedicine.medical_specialtyAnemiaMicrocytic anemia030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineCeliac arterymedicine.arteryInternal medicinemedicineAorta AbdominalAortaHematologyThrombocytosisAnemia Iron-Deficiencybusiness.industryGeneral MedicineHematologymedicine.diseaseThrombosisIron-deficiency anemia030220 oncology & carcinogenesisThrombosiCardiologyThrombocytosiFemalebusinessHuman
researchProduct

Occlusion of the abdominal aorta during coronary angiography with fractional flow reserve due to migration of the left ventricle thrombus in a patien…

2019

Coronary angiographymedicine.medical_specialtyThrombocytosisbusiness.industrylcsh:RAbdominal aortalcsh:MedicineFractional flow reservemedicine.diseasemedicine.anatomical_structureImage in InterventionVentriclemedicine.arteryInternal medicineOcclusionmedicineCardiologyThrombusCardiology and Cardiovascular MedicinebusinessPostępy w Kardiologii Interwencyjnej
researchProduct

Germline JAK2 L611S mutation in a child with thrombocytosis

2018

GeneticsThrombocytosisThrombocytosisPlatelet CountInfantHematologyExonsBiologyJanus Kinase 2medicine.diseaseGermline03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisMutation (genetic algorithm)MutationmedicineHumansOnline Only ArticlesGerm-Line Mutation030215 immunology
researchProduct

Mediterranean Diet Maintained Platelet Count within a Healthy Range and Decreased Thrombocytopenia-Related Mortality Risk: A Randomized Controlled Tr…

2021

There is little information on the dietary modulation of thrombosis-related risk factors such as platelet count. We aimed to assess the effects of Mediterranean diet (MedDiet) on platelet count and related outcomes in an older population at high cardiovascular risk. In participants of the PREDIMED (PREvención con DIeta MEDiterránea) study, we assessed whether an intervention with a MedDiet enriched with extra-virgin olive oil or nuts, relative to a low-fat control diet, modulated platelet count (n = 4189), the risk of developing thrombocytosis and thrombocytopenia (n = 3086), and the association between these alterations and all-cause mortality (median follow-up time: 3.0 years). Although p…

Male0301 basic medicineMediterranean dietthrombocytopenia030204 cardiovascular system & hematologyDiet Mediterraneanlaw.inventionClinical trials0302 clinical medicinepreventionRandomized controlled triallawPlateletThrombocytosisNutrition and DieteticsFactors de risc en les malaltiesIncidenceIncidence (epidemiology)Hazard ratioFemaleDietalcsh:Nutrition. Foods and food supplymedicine.medical_specialtyRisk factors in diseaseslcsh:TX341-641ArticleOlder population03 medical and health sciencesMediterranean cookingMediterranean dietInternal medicineCuina mediterràniamedicineHumansAgedProportional Hazards ModelsThrombocytosisPlatelet Countbusiness.industryplatelet countmedicine.diseaseConfidence intervalDiet030104 developmental biologyHeart Disease Risk Factorsrandomized controlled trialbusinessAssaigs clínicsFood ScienceNutrients
researchProduct

A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals.

2004

Myelodysplastic syndromes (MDS) show occasionally thrombocytosis, common feature of myeloproliferative diseases (MPD), with the overlapping of both disorders. Classically, thrombocytosis has been associated with some MDS subtypes: refractory anaemia with ringed sideroblasts (RARS), 5q- syndrome and those MDS with 3q chromosome rearrangements. The recent WHO classification recognises an unclassifiable MDS/MPD category including some of these disorders. Our aim is to determine the frequency of presentation, subtype classification and chromosome abnormalities of MDS with thrombocytosis diagnosed in our institution. Between 1990 and 2003 we studied 317 SMD patients according to FAB and WHO revi…

MaleCancer ResearchPathologymedicine.medical_specialtyRefractory anemia with ringed sideroblastsWorld Health OrganizationAge Distributionhemic and lymphatic diseasesInternal medicinemedicineHumansSurvival analysisAgedRetrospective StudiesAged 80 and overThrombocytosisThrombocytosisbusiness.industryMyelodysplastic syndromesRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurvival AnalysisOncologyInternational Prognostic Scoring SystemDysplasiaKaryotypingMyelodysplastic SyndromesFemalebusinessRefractory cytopenia with multilineage dysplasiaLeukemia research
researchProduct

Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis

2020

Made available in DSpace on 2021-06-25T10:38:01Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-11-01 Healthway Objective. To develop a composite disease activity score for systemic JIA (sJIA) and to provide preliminary evidence of its validity. Methods. The systemic Juvenile Arthritis Disease Activity Score (sJADAS) was constructed by adding to the four items of the original JADAS a fifth item that aimed to quantify the activity of systemic features. Validation analyses were conducted on patients with definite or probable/possible sJIA enrolled at first visit or at the time of a flare, who had active systemic manifestations, which should include fever. Patients were reassessed 2 wee…

MaleClinical assessment; Composite disease activity score; Disease activity; Outcome measures; Pediatric rheumatology; Still's disease; Systemic juvenile idiopathic arthritismedicine.medical_specialtyFeverClinical assessmentComposite disease activity scoreArthritisLymphadenopathyDiseaseSeverity of Illness IndexOutcome measuresOutcome measureJuvenile Arthritis Disease Activity ScoreRheumatologyCronbach's alphaSystemic juvenile idiopathic arthritisInternal medicineStill's diseaseContent validityMedicineJuvenileHumansPharmacology (medical)Pediatric rheumatologyDisease activityRange of Motion ArticularChildPain MeasurementSerositisThrombocytosisbusiness.industryConstruct validityReproducibility of ResultsAnemiaExanthemamedicine.diseaseArthralgiaRheumatologyArthritis JuvenileChild PreschoolSplenomegalyQuality of LifeFemaleHyperferritinemiabusinessHepatomegaly
researchProduct

Presence of calreticulin mutations in JAK2-negative polycythemia vera

2014

Abstract Calreticulin (CALR) mutations have recently been reported in JAK2- and MPL-negative Myeloproliferative Neoplasms (MPN), particularly essential thrombocythemia (ET) and primary myelofibrosis (PMF).The clinical course of sporadic CALR-mutated patients seems to be more indolent than that of JAK2-mutated patients. In contrast, no CALR mutation has been found in the 647 published cases of Polycythemia Vera (PV) patients tested. Consequently, CALR mutations were considered exclusive to JAK2 and MPL mutations. Since 98% of PV patients harbor a JAK2 mutation (mostly the V617F mutation in exon 14 and more rarely, in exon 12), the absence of CALR mutations in PV seemed logical. Here, we desc…

MaleErythrocytesMESH: Thrombocytosismedicine.disease_causeMESH: Polycythemia VeraBiochemistryMESH: Janus Kinase 2MESH: GenotypeHemoglobinsMESH: Aged 80 and overPolycythemia verahemic and lymphatic diseasesPolycythemia VeraMESH: HeterozygoteAged 80 and overThrombocytosisMESH: AgedMutation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyJanus kinase 2biologyMESH: ErythrocytesExonsHematologyLeukemiaMESH: HemoglobinsMESH: Primary MyelofibrosisThrombocythemia EssentialHeterozygoteMESH: MutationGenotypeMESH: CalreticulinImmunologyContext (language use)medicineHumansMyelofibrosisAllelesAgedMESH: HumansEssential thrombocythemiabusiness.industryMESH: AllelesCell BiologyJanus Kinase 2medicine.diseaseMESH: MalePrimary MyelofibrosisMESH: Gene DeletionMutationImmunologybiology.proteinCancer researchMESH: Thrombocythemia EssentialCalreticulinMESH: ExonsbusinessCalreticulinGene Deletion[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBlood
researchProduct